Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Lilly Asia Ventures
AddedFeb 13, 2024
UpdatedJul 16, 2026
Lilly Asia Ventures

Lilly Asia Ventures

Operating

Lilly Asia Ventures: A pioneering biomedical venture capital firm, independently managing investments since 2008.

Location
Shanghai, Shanghai, CN
Founded
2008
Firm
Compare
Portfolio
Employees

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto.

Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical vent... Read more

Lilly Asia Ventures - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments44
Current Portfolio Count25
Total Portfolio Exits1

Top Investment Stages

Series B17 (40.5%)
Series A15 (35.7%)
Series C7 (16.7%)
Series E2 (4.8%)
Post Ipo Equity1 (2.4%)

Stage Mix

Series B 40%Series A 36%Series C 17%Series E 5%Post Ipo Equity 2%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Comanche Biopharma logo

Comanche Biopharma

Synnovation Therapeutics logo

Synnovation Therapeutics

Precede Biosciences logo

Precede Biosciences

Akura Medical logo

Akura Medical

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

Rgenta Therapeutics logo

Rgenta Therapeutics

Sonoma Biotherapeutics logo

Sonoma Biotherapeutics

Insilico Medicine logo

Insilico Medicine

Synthekine logo

Synthekine

NiKang Therapeutics logo

NiKang Therapeutics

Fortis Therapeutics logo

Fortis Therapeutics

Regor Therapeutics logo

Regor Therapeutics

Terns Pharmaceuticals logo

Terns Pharmaceuticals

Dmed logo

Dmed

Sonoma Pharmaceuticals logo

Sonoma Pharmaceuticals

Legend Biotech logo

Legend Biotech

Ansun Biopharma logo

Ansun Biopharma

NextCure logo

NextCure

KSQ Therapeutics logo

KSQ Therapeutics

Magnolia Neurosciences logo

Magnolia Neurosciences

Alector logo

Alector

Innovent Biologics logo

Innovent Biologics

Tmunity Therapeutics logo

Tmunity Therapeutics

Tempest Therapeutics logo

Tempest Therapeutics

Gritstone bio logo

Gritstone bio

Lilly Asia Ventures - Similar Investment Firms

Trans-Pacific Ventures logo

Trans-Pacific Ventures

Lanting Capital logo

Lanting Capital

AsiaTech Ventures logo

AsiaTech Ventures

Libra Capital Ventures logo

Libra Capital Ventures

Avalanche Asia Star Fund logo

Avalanche Asia Star Fund

Insignia Ventures Partners logo

Insignia Ventures Partners

insignia.vc

LongRiver Investments logo

LongRiver Investments

Asia Investment Capital logo

Asia Investment Capital

Healthcare Ventures logo

Healthcare Ventures

hcven.com

Mistry Ventures logo

Mistry Ventures

Ming Bioventures logo

Ming Bioventures

Aspen Ventures logo

Aspen Ventures

Horizons Ventures logo

Horizons Ventures

WuXi Healthcare Ventures logo

WuXi Healthcare Ventures

Mirae Asset Venture Investment logo

Mirae Asset Venture Investment

Lilly Asia Ventures - Classification

NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified
Show 6 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
  • 523940Portfolio Management and Investment Advice
SIC
  • 6000Depository Institutions
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end